• DOPE in LNP Design: Fusion, Evidence, and Limits

  2026-10-09

  Explore how 1,2-Dioleoyl-sn-glycero-3-PE (DOPE) influences membrane packing, endosomal escape, and nucleic acid delivery. This evidence-led analysis also distinguishes established DOPE mechanisms from emerging zwitterionic lipid research in mRNA cancer vaccines.

• FAM134B, ER-Phagy, and Salmonella Infection

  2026-10-08

  A 2025 Nature Communications study identifies the ER-phagy receptor FAM134B as a host defense factor targeted by Salmonella Typhimurium through the bacterial effector SopF. Genetic, cellular, and mouse-model evidence supports a mechanism in which impaired FAM134B oligomerization suppresses ER-phagy and increases intracellular bacterial burden, while also highlighting important limits on how broadly the findings can be generalized.

• Amikacin Disulfate: Mechanism and Evidence

  2026-10-08

  Amikacin disulfate is a semisynthetic aminoglycoside antibiotic used to study 16S rRNA recognition, bacterial protein synthesis suppression, and resistance biology. Peer-reviewed evidence also shows amikacin can form complexes with lysozyme, but that finding does not establish bacterial efficacy or clinical performance.

• Carvedilol: β-Blockade and HCT Regeneration

  2026-10-07

  Carvedilol is a nonselective β-adrenergic receptor antagonist with α1-adrenergic activity. A 2025 mouse-to-human study associated nonselective β-blockade with impaired hematopoietic regeneration after allogeneic transplantation, while leaving receptor-level causality unresolved.

• Cefiderocol Against Resistant Pseudomonas and Acinetobacter

  2026-10-07

  A large European surveillance study found that cefiderocol retained high in vitro activity against Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and several newer β-lactam/β-lactamase inhibitor combinations. The study’s value lies in its direct, contemporary comparison of resistance phenotypes and genomic findings, while its clinical implications remain bounded by the in vitro design.

• Gentamycin Sulfate in Resistance Research

  2026-10-06

  A translational perspective on Gentamycin Sulfate as a mechanistic probe for bacterial protein synthesis research, ribosome function analysis, and the interpretation of resistance findings in Gram-negative pathogens.

• Neuroligin 1, Striatal D2-MSNs, and Repetitive Behavior

  2026-10-06

  A study in Advanced Science links Neuroligin 1 loss in dorsal-striatal D2 receptor-expressing medium spiny neurons to excessive self-grooming and digging in mice. Its combination of cell-type-specific behavioral analysis, neuronal activity measurements, single-nucleus RNA sequencing, and protein validation identifies PKC overactivation as a candidate molecular contributor while leaving important questions about isoform specificity and relevance to human autism.

• Five Questions About ATP Luminescence in Ferroptosis

  2026-10-05

  A source-grounded guide to what ATP-based luciferase luminescence measures, how it relates to ferroptosis research, and where evidence, interpretation, and applicability remain limited.

• Biotin-XX Tyramide Reagent for Surface Biology

  2026-10-05

  Biotin-XX Tyramide Reagent, also known as biotin-LC-LC-tyramide, offers a membrane-impermeant perspective on low-abundance surface molecules. This article explains how its chemistry can help interpret activity-dependent synaptic biology without confusing surface localization with total protein abundance.

• Cy5 Amine (Non-Sulfonated): Product Overview

  2026-10-04

  Cy5 amine (non-sulfonated), SKU A8143, is a supplier-described primary-amine cyanine dye for conceptual fluorescent biomolecule-labeling applications. No matched paper evidence is available for independent performance assessment.

• Angiotensin I/II (1-5): Product Overview

  2026-10-03

  APExBIO lists Angiotensin I/II (1-5) as an Asp-Arg-Val-Tyr-Ile peptide fragment for conceptual renin-angiotensin system research. No matched paper evidence was supplied, so biological performance and research outcomes are not independently established here.

• CLCC1 and Herpesvirus Nuclear Egress Fusion

  2026-10-02

  This preprint identifies the host protein CLCC1 as an essential factor in the membrane-fusion step of herpesvirus nuclear egress. A whole-genome CRISPR screen with HSV-1, combined with cellular and evolutionary analyses, links CLCC1 loss to perinuclear capsid accumulation, reduced viral production, and defective nuclear pore insertion.

• HRP Goat Anti-Mouse IgG (H+L) Antibody

  2026-10-01

  HRP Goat Anti-Mouse IgG (H+L) Antibody K1221 provides an HRP-labeled secondary reagent for detecting mouse-derived primary antibodies in Western blotting, ELISA, IHC, and ICC. It should be selected when the primary antibody is from mouse and a validated HRP detection system is available; it is not a substitute for a primary antibody or a fluorescence-only secondary reagent.

• Cefiderocol in Resistant P. aeruginosa and Acinetobacter

  2026-10-01

  This European multicenter study shows that cefiderocol retained high in vitro activity against Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and several newer β-lactam/β-lactamase inhibitor combinations. Its integrated susceptibility and genomic analysis clarifies how cefiderocol resistance differs from resistance to other agents and supports parallel susceptibility testing in resistance-focused research.

• Angiotensin I/II (1-5) RAS Workflow Guide

  2026-09-30

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving vascular, renal, blood pressure, and aldosterone-related workflows. It should not be treated as a validated substitute for intact angiotensin peptides or used in unrelated signaling assays without assay-specific qualification.

8133 records 1/543 page Next 12345 下5页 Last page